Tafasitamab-cxix is a monoclonal antibody directed against CD19 that elicits antibody-dependent cell-mediated cytotoxicity. This is an adaptive immune response that occurs when immune cells recognize antibody-coated cancer cells for destruction and trigger cell lysis.
The drug is indicated in combination for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.